GlassScriptPhysician profile
Thomas Mani Kurian
NPI 1356675573
$26,602.32
in general payments reported to CMS, 2019-2025
72 companies · $5,194 in 2025
The $5,194 reported for 2025 was more than what 86% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,548 · 2020: $1,838 · 2021: $2,922 · 2022: $4,435 · 2023: $4,266 · 2024: $5,399 · 2025: $5,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,619.77 |
| Education | $239.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,728.27 | 2021-2025 | |
| Ucb, INC. | $1,934.59 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $1,905.65 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lilly USA, LLC | $1,389.03 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Sk Life Science, INC. | $1,233.83 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $1,077.58 | 2019-2025 | |
| Neurelis, INC. | $996.74 | 2020-2025 | Valtoco |
| Eisai INC. | $961.95 | 2019-2025 | |
| Biogen, INC. | $885.92 | 2019-2025 | Vumerity, Tysabri |
| Mdd US Operations, LLC | $826.16 | 2022-2025 | Gocovri, Apokyn, Apokyn |
| Amgen INC. | $776.77 | 2019-2025 | Uplizna, Aimovig |
| Genentech USA, INC. | $732.60 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Pfizer INC. | $685.99 | 2023-2025 | |
| Tg Therapeutics, INC. | $532.28 | 2022-2025 | |
| Genzyme Corporation | $510.75 | 2019-2023 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $509.53 | 2019-2022 | |
| Emd Serono, INC. | $470.02 | 2019-2025 | Mavenclad |
| Sunovion Pharmaceuticals INC. | $457.94 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $416.49 | 2022-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $393.31 | 2021-2025 | Vyepti |
| Supernus Pharmaceuticals, INC. | $359.91 | 2019-2025 | Qelbree |
| Octapharma USA, INC. | $349.27 | 2022-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Biohaven Pharmaceuticals, INC. | $339.72 | 2021 | |
| Greenwich Biosciences, INC. | $325.18 | 2019 | |
| Celgene Corporation | $306.94 | 2022-2025 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $296.88 | 2021-2025 | Andexxa, Wainua |
| Upsher-Smith Laboratories LLC | $275.22 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $259.90 | 2019-2024 | Amvuttra, Onpattro |
| Abbott Laboratories | $248.71 | 2019-2025 | Ensite Precision, Infinity, Perclose Prostyle |
| Argenx US, INC. | $220.68 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Tonix Medicines, INC. | $207.46 | 2025 | Zembrace Symtouch |
| Avanir Pharmaceuticals, INC. | $178.09 | 2019-2021 | |
| Acorda Therapeutics, INC | $172.27 | 2019-2022 | |
| Janssen Biotech, INC. | $170.37 | 2025 | |
| Livanova USA, INC. | $159.31 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Kyowa Kirin, INC. | $151.95 | 2019-2024 | Nourianz |
| Csl Behring | $145.85 | 2021-2024 | Hizentra |
| Alexion Pharmaceuticals, INC. | $142.49 | 2021-2025 | Ultomiris |
| Akcea Therapeutics, INC. | $140.73 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $134.95 | 2022-2025 | Purified Cortrophin Gel |
| Acadia Pharmaceuticals INC | $133.01 | 2023-2025 | Nuplazid, Daybue |
| Mallinckrodt Hospital Products INC. | $129.75 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $129.30 | 2019-2025 | Crexont, Rytary |
| Chiesi USA, INC. | $100.02 | 2019 | |
| Merz Pharmaceuticals, LLC | $99.48 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Assertio Therapeutics, INC. | $90.95 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $84.55 | 2022 | |
| Sumitomo Pharma America, INC. | $80.72 | 2023-2024 | Aptiom |
| Otsuka America Pharmaceutical, INC. | $72.39 | 2024 | Nuedexta, Rexulti |
| Impel Pharmaceuticals INC. | $66.08 | 2022-2023 | Trudhesa |
| Almatica Pharma LLC | $64.97 | 2021 | |
| Arbor Pharmaceuticals, INC. | $63.19 | 2019-2021 | |
| Medtronic, INC. | $46.43 | 2025 | Aurora Ev-Icd Mri Surescan |
| Sobi, INC | $38.61 | 2021 | |
| Collegium Pharmaceutical, INC. | $37.40 | 2022 | |
| Biomarin Pharmaceutical INC. | $33.35 | 2024-2025 | Brineura |
| Vanda Pharmaceuticals INC. | $29.94 | 2025 | Ponvory |
| Cycle Pharmaceuticals INC | $27.06 | 2025 | Bafiertam, Tascenso Odt |
| Mallinckrodt Enterprises LLC | $25.68 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.95 | 2021 | |
| Azurity Pharmaceuticals, INC. | $24.83 | 2024 | Horizant |
| Promius Pharma LLC | $24.67 | 2019 | |
| Tanabe Pharma America, INC. | $22.64 | 2019 | |
| Grifols USA, LLC | $22.43 | 2024 | Gamunex-C |
| Scilex Pharmaceuticals INC. | $21.30 | 2023 | Ztlido |
| Portola Pharmaceuticals, LLC | $20.42 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $19.51 | 2022 | |
| Adamas Pharmaceuticals, INC. | $18.59 | 2019 | |
| Ceribell, INC. | $16.59 | 2022 | |
| Boston Scientific Corporation | $12.60 | 2020 | |
| Dynasplint Systems INC. | $8.80 | 2023 | Dynasplint |
| Travere Therapeutics, INC. | $0.83 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kurian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.